Bayer's Legal Blitz Collides With Financial Reality as Stock Rally Faces a Credibility Test

Bayer shares rally 40% in month on Supreme Court glyphosate ruling; Jefferies warns €33B debt blocks breakup, RSI overbought.

The shares added almost 40% in a month. A 7–2 Supreme Court ruling gave Bayer the legal ammunition it needed. And on the back of that momentum, the company moved over the weekend to dismiss roughly 4,000 consolidated glyphosate lawsuits pending before U.S. federal courts. Yet just as the rally pushed the stock to €53.86 on July 3 — its 52-week high — analysts at Jefferies poured cold water on the narrative, warning that a rapid breakup of the conglomerate remains a distant prospect.

The dismissal motion relies squarely on the high court's late-June decision in Monsanto v. Durnell, which held that the federal pesticide law FIFRA preempts state-law failure-to-warn claims. With the EPA having repeatedly classified glyphosate as non-carcinogenic and approved labels without cancer warnings, Bayer argues the legal foundation for thousands of pending cases has collapsed. To further isolate the litigation risk, CEO Bill Anderson folded the entire U.S. glyphosate business into a newly created entity called Ruveon LLC — a structural move that market observers interpret as a step toward eventual separation of the Crop Science division.

The legal offensive, however, runs parallel to an overstretched balance sheet. Jefferies analyst Michael Leuchten retained a "Hold" rating and a €46 price target on July 13, stressing that net debt of roughly €33 billion and material cash outflows restrict Bayer's strategic options. "The balance sheet must be strengthened and the pharmaceuticals business stabilized before a split becomes financially viable," Leuchten argued. That caution stands in contrast to the buoyant equity story: the stock closed Friday at €50.18, then dipped to €50.04 at Monday's open — a fractional 0.28% retreat that feels more like a pause than a reversal.

Bayer's agribusiness valuation has drawn a natural benchmark from BASF, which plans an IPO of its crop protection unit in the second quarter of 2027, targeting a valuation between €20 billion and €30 billion. Bayer's Crop Science is significantly larger, and investors have used the BASF yardstick to estimate the implied worth of Bayer's own agricultural arm — a key driver behind the stock's 31.6% year-to-date advance. Yet the German rival's spin-off timeline remains years away, and Bayer faces more immediate refinancing hurdles. The recent €3 billion deal with Apollo for the LARC contraceptive franchise covers only part of looming bond maturities, and the company's guidance for negative free cash flow in 2026 remains an open question that the August 7 second-quarter earnings report must address.

The technical picture reinforces the need for caution. The 14-day relative strength index hit 70.4 on Friday — the classic overbought threshold — and dipped only slightly to 69.6 as trading resumed at the start of the week. The stock now trades 33.2% above its 200-day moving average of €37.68, a gap that underscores the velocity of the rally. Annualized 30-day volatility hovers near 61.9%, unusually high for a DAX constituent, signaling that sharp swings are likely to persist as markets wait for fresh cues from the courtroom.

Two calendar items will define the near-term direction. On August 7, Bayer reports second-quarter results, offering a check on whether operational improvements in the pharma business can offset the drag from litigation expenses and cash outflows. Then, on August 19, a Missouri federal court will rule on the proposed $7.25 billion glyphosate class-action settlement. In the interim, market participants are watching for any preliminary signal from District Judge Vincent Chhabria regarding the dismissal motion — a positive nod could lift the stock before the August hearing.

For now, Bayer's rally rests on a fragile truce between legal optimism and financial reality. The Supreme Court win and the aggressive motion to dismiss thousands of cases have dramatically improved the risk profile, but the debt load and the negative free cash flow forecast prevent the kind of clean break-up story that the share price seems to be pricing in. Whether the current level proves sustainable depends on whether the court delivers a clean exit from the Roundup overhang — and on whether the underlying business can generate enough cash to fund a future separation without relying on further financial engineering.